All News #Library
Others
PsychoGenics Announces Exclusive Global License for an IND-Ready ENT1 Inhibitor
01 Dec 2023 //
BUSINESSWIRE
PsychoGenics Launches an Updated Corporate Identity and Brand
10 Nov 2023 //
BUSINESSWIRE
PsychoGenics and Collaborations Pharmaceuticals awarded a $1M grant
05 Sep 2023 //
BUSINESSWIRE
PsychoGenics on board for Iama`s Dravet syndrome study
19 Jan 2023 //
FIERCE BIOTECH
IAMA and Psychogenics Sign a Preclinical Study Agreement for Dravet Syndrome
12 Jan 2023 //
BUSINESSWIRE

Market Place
Sourcing Support